Skip to main content

DiPT Facts

Psychedelic; Substituted tryptamine; Serotonin 2A receptor agonist

Description

DiPT (N,N-diisopropyltryptamine) is a synthetic psychedelic of the tryptamine class. It activates serotonin receptors in the brain, producing the altered sound perception that defines it.[1]

Subjective effects include downward pitch shifting, distorted harmonics, auditory hallucinations, and alien restructuring of familiar sounds. The experience is defined by sound — music and voices become strange while vision stays largely normal, the opposite of a typical psychedelic.

DiPT produces no physical dependence, and no lethal dose has been established.[2] The primary physical danger is combining it with MAOIs — DiPT activates serotonin receptors and slows serotonin clearance, so adding an MAOI risks dangerous serotonin buildup and a life-threatening overheating response.[3]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight15 – 30 mgCommon30 – 60 mgStrong60 – 100 mgHeavy100+ mg

Starts in 30 – 60 minLasts 3 – 8 hoursAfter-effects 2 – 4 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
Low
Physical dependence
None
Psychological dependence
Negligible
Withdrawal
None recorded
Compulsive redosing
Negligible

Tolerance

Builds
Rapid
Fully resets after
7 days
Carries over to
LSD; psilocybin; DMT; mescaline; 5-MeO-DiPT; DPT

Effectslikely at a common dose

Perception
Auditory distortion; Music enhancement; +6 possible, including Tinnitus
Body
none likely · 11 possible, including Nausea, Muscle tension, Abnormal heartbeat
Feeling
none likely · 2 possible, including Anxiety

Who shouldn't take it

Absolute
Psychotic disorders; Pregnancy; Lithium use; MAOI co-administration
Relative
Cardiovascular disease; Bipolar disorder

Combinations61 recorded

Lethal (1)
MAOIs
Dangerous (19)
MDMA, MDA; Alpha-2 adrenergic receptor antagonist; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ibogaine; Ketamine, DXM, PCP; Lithium; Local anesthetics; MDMA, Amphetamines; NDRIs (Wellbutrin); NRIs; Psychedelics; Salvia, Ibogaine; SNRIs; SSRIs; Stimulants; Synthetic cannabinoids
Caution (37)
See full page: psychedex.org/substances/dipt
Not graded (4)
Not listed never means safe.

Seek help immediately if

Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:

  • Very high body temperature; hot, dry skin
  • Seizures
  • Chest pain; fast or irregular heartbeat
  • Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
  • Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
  • Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm

What to do

  1. Stay calm and reassure — remind them they took a drug and the effect will pass
  2. Move to a calm, quiet, safe space with low light; reduce noise and sensory input
  3. Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
  4. Talk them down gently; don't grab or restrain unless they're in danger
  5. For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
  6. If overheating, cool the body; be ready to give rescue breaths / CPR

The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (2014) Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. — Psychopharmacology doi:10.1007/s00213-014-3557-7
  2. [2]
    ^Nichols DE (2016) Psychedelics — Pharmacological Reviews doi:10.1124/pr.115.011478
  3. [3]
    ^Yu AM (2008) Indolealkylamines: biotransformations and potential drug-drug interactions — The AAPS Journal doi:10.1208/s12248-008-9028-5
Print version
Report an issue